Neurokine Pharmaceuticals Inc.

FY: Jan 31 2026

FY: Jan 31 2025

FY: Jan 31 2024

FY: Jan 31 2023

FY: Jan 31 2023

FY: Jan 31 2022

FY: Jan 31 2022

FY: Jan 31 2021

FY: Jan 31 2021

FY: Jan 31 2021

FY: Jan 31 2020

FY: Jan 31 2020

FY: Jan 31 2020

Q: Apr 30 2019

Q: Apr 30 2019

FY: Jan 31 2019

FY: Jan 31 2019

Q: Oct 31 2018

Q: Oct 31 2018

Q: Jul 31 2018

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

05,06b,4a5

Notice of Effectiveness

Amended Initial Registration Statement

Amended Initial Registration Statement

Amended Initial Registration Statement

Registration (IPO) statement under Securities Act of 1933

Definitive Proxy Statement

Definitive Proxy Statement

Definitive Proxy Statement

Definitive Proxy Statement

Required Information in Proxy Statement

Required Information in Proxy Statement

Preliminary Proxy Statement

Definitive Proxy Statement

Preliminary Proxy Statement

RA CAPITAL MANAGEMENT, L.P.

Doroudian Ahmad

Doroudian Ahmad

Doroudian Ahmad

ONG MOIRA

BORMANN-KENNEDY BARBARA-JEAN ANNE

Salari Hassan

Letter from the SEC

Letter from the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC